Obsidian Therapeutics
Obsidian Therapeutics is seeking a Research Associate (Contractor) to support viral vector engineering and production within its Cell Therapy Research Team. The role involves generating retroviral and lentiviral vectors, performing titration and transduction of T cells, and supporting the isolation and characterization of primary tumor and immune cells. This lab-based position is based in Cambridge, MA, with a planned relocation to Bedford, MA in Q2 2027.
Headquarters
Cambridge, Massachusetts, United States
Obsidian Therapeutics is a clinical-stage biotechnology company using its proprietary cytoDRiVE® platform to engineer novel TIL (tumor-infiltrating lymphocyte) cell therapies. The platform leverages drug-responsive domains (DRDs) to regulate protein function using an FDA-approved small-molecule drug. The company's lead program, OBX-115 (amsoki-cel), is being evaluated in advanced melanoma in a Phase 1/2 clinical trial.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Obsidian Therapeutics.
Senior Scientist Vector Engineering
AstraZeneca
Senior Scientist - Lentiviral Vectors
Revvity Signals
Senior Scientist Vector Engineering
AstraZeneca
Senior Scientist Vector Engineering
AstraZeneca
Senior Research Associate – Scientist II, Molecular Biology & Viral Vector Platforms
Adicet Bio
Senior Scientist Vector Engineering
AstraZeneca